Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics

  • Authors:
    • Hui Wang
    • Ying Wang
    • Elizabeth R. Rayburn
    • Donald L. Hill
    • John J. Rinehart
    • Ruiwen Zhang
  • View Affiliations

  • Published online on: April 1, 2007     https://doi.org/10.3892/ijo.30.4.947
  • Pages: 947-953
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Dexamethasone (DEX) is mainly used as an anti-emetic agent in cancer therapy. We have recently demonstrated that DEX pretreatment increases the antitumor activity of the cancer chemotherapeutic agents carboplatin and gemcitabine, and decreases host toxicity in nude mouse xenograft models of human cancer. However, the underlying mechanisms are not fully understood. The present study was designed to determine the effects of DEX pretreatment on the anticancer activity of adriamycin (ADR) in a syngeneic model of breast cancer (4T1), emphasizing the effects of DEX on cytokine expression and modulation of ADR pharmacokinetics. We have demonstrated five major new findings about DEX pretreatment: a) it enhances the therapeutic effect of ADR, inducing almost complete inhibition of tumor growth; b) it increases tumor ADR accumulation; c) it modulates the expression of cytokines produced by the tumor, increasing TNFα and decreasing IL-1β and VEGF expression; d) it enhances the effects of ADR on induction of apoptosis and inhibition of cell proliferation; and e) it suppresses nuclear NFκB activation and inhibits ADR-induced NFκB activation, possibly via IκB up-regulation. These findings suggest that DEX can be used as a chemosensitizer and chemoprotectant. These results provide a rationale for the expanded clinical use of DEX for cancer therapy.

Related Articles

Journal Cover

April 2007
Volume 30 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, H., Wang, Y., Rayburn, E.R., Hill, D.L., Rinehart, J.J., & Zhang, R. (2007). Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. International Journal of Oncology, 30, 947-953. https://doi.org/10.3892/ijo.30.4.947
MLA
Wang, H., Wang, Y., Rayburn, E. R., Hill, D. L., Rinehart, J. J., Zhang, R."Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics". International Journal of Oncology 30.4 (2007): 947-953.
Chicago
Wang, H., Wang, Y., Rayburn, E. R., Hill, D. L., Rinehart, J. J., Zhang, R."Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics". International Journal of Oncology 30, no. 4 (2007): 947-953. https://doi.org/10.3892/ijo.30.4.947